Helen Kim

Helen Kim is Vice President of Regulatory Affairs, overseeing both Regulatory and Clinical Quality Affairs functions. She has over 25 years of experience in the biotechnology/pharmaceutical industry spanning clinical development through commercialization with an emphasis in cell and gene therapy in the past 20 years.
Prior to Umoja, Helen led the US FDA approval activities for Juno, Celgene, and Bristol Myers Squibb’s CAR T portfolio, including for BREYANZI in LBCL. Prior to Juno, she led the regulatory activities for Dendreon’s approval of PROVENGE, the first autologous product for the treatment of advanced prostate cancer. Before Dendreon, she worked on the regulatory advances of the EchoGen® (perflenapent emulsion) at Sonus Pharmaceuticals, an intravenously injectable fluorocarbon‐based ultrasound contrast agent, in the United States and Europe.
Helen holds a B.S. degree in Animal Sciences from UC Davis.